MRTX
Price:
$58.7
Market Cap:
$4.12B
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase 3 clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib. Mirati Thera...[Read more]
Industry
Biotechnology
IPO Date
2013-07-15
Stock Exchange
NASDAQ
Ticker
MRTX
According to Mirati Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 3.91B. This represents a change of 73.06% compared to the average of 2.26B of the last 4 quarters.
The mean historical Enterprise Value of Mirati Therapeutics, Inc. over the last ten years is 2.48B. The current 3.91B Enterprise Value has changed 15.67% with respect to the historical average. Over the past ten years (40 quarters), MRTX's Enterprise Value was at its highest in in the December 2020 quarter at 9.32B. The Enterprise Value was at its lowest in in the December 2016 quarter at 37.93M.
Average
2.48B
Median
749.83M
Minimum
37.25M
Maximum
8.53B
Discovering the peaks and valleys of Mirati Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 734.01%
Maximum Annual Enterprise Value = 8.53B
Minimum Annual Increase = -90.95%
Minimum Annual Enterprise Value = 37.25M
Year | Enterprise Value | Change |
---|---|---|
2022 | 2.36B | -67.36% |
2021 | 7.24B | -15.11% |
2020 | 8.53B | 93.36% |
2019 | 4.41B | 305.65% |
2018 | 1.09B | 250.14% |
2017 | 310.71M | 734.01% |
2016 | 37.25M | -90.95% |
2015 | 411.77M | 86.83% |
2014 | 220.40M | 29.92% |
2013 | 169.64M | 227.51% |
The current Enterprise Value of Mirati Therapeutics, Inc. (MRTX) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages
3-year avg
6.05B
5-year avg
4.73B
10-year avg
2.48B
Mirati Therapeutics, Inc.’s Enterprise Value is less than Reata Pharmaceuticals, Inc. (6.68B), less than Sarepta Therapeutics, Inc. (13.28B), less than Krystal Biotech, Inc. (4.95B), greater than Intercept Pharmaceuticals, Inc. (915.81M), greater than Day One Biopharmaceuticals, Inc. (1.01B), greater than Amylyx Pharmaceuticals, Inc. (89.50M), greater than Terns Pharmaceuticals, Inc. (458.36M), less than Apellis Pharmaceuticals, Inc. (5.11B), less than Madrigal Pharmaceuticals, Inc. (0), less than Viking Therapeutics, Inc. (4.91B), less than Hepion Pharmaceuticals, Inc. (5.95B), greater than PTC Therapeutics, Inc. (2.24M), greater than Akero Therapeutics, Inc. (2.17B), greater than null (1.56B),
Company | Enterprise Value | Market cap |
---|---|---|
6.68B | $6.57B | |
13.28B | $12.29B | |
4.95B | $5.29B | |
915.81M | $794.69M | |
1.01B | $1.25B | |
89.50M | $161.36M | |
458.36M | $549.60M | |
5.11B | $5.00B | |
0 | $5.30B | |
4.91B | $6.00B | |
5.95B | $4.20M | |
2.24M | $2.43B | |
2.17B | $1.83B | |
1.56B | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Mirati Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Mirati Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Mirati Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Mirati Therapeutics, Inc. (MRTX)?
What is the 3-year average Enterprise Value for Mirati Therapeutics, Inc. (MRTX)?
What is the 5-year average Enterprise Value for Mirati Therapeutics, Inc. (MRTX)?
How does the current Enterprise Value for Mirati Therapeutics, Inc. (MRTX) compare to its historical average?